Heart drug shows promise in shrinking High-Risk prostate cancer before surgery
NCT ID NCT07311915
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This study tests whether adding a common heart medication (propranolol) to standard hormone therapy before prostate removal can improve outcomes for men with high-risk prostate cancer. About 30 participants will receive the combination treatment for several months before surgery. The goal is to see if this approach can eliminate or greatly reduce the cancer in the removed prostate tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongda Hospital
Nanjing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.